Targets › ITGB1
4 programs from 4 companies in 4 trials: 3 Phase 2, 1 Phase 4; Neurology, Respiratory, Oncology; next expected readout Jul 2027.
Integrins alpha-1/beta-1, alpha-2/beta-1, alpha-10/beta-1 and alpha-11/beta-1 are receptors for collagen. Integrins alpha-1/beta-1 and alpha-2/beta-2 recognize the proline-hydroxylated sequence G-F-P-G-E-R in collagen. (UniProt, P05556)
Open in Phaseline: the race on ITGB1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The Cleveland Clinic | Natalizumab Integrin alpha-4/beta-7 inhibitor; Integrin alpha-4/beta-1 inhibitor | ITGA4, ITGB7, ITGB1 | Phase 4 | Multiple Sclerosis, Relapsing-Remitting | Jul 2027 |
| Queen Mary University of London | Natalizumab Integrin alpha-4/beta-7 inhibitor; Integrin alpha-4/beta-1 inhibitor | ITGA4, ITGB7, ITGB1 | Phase 2 | Multiple Sclerosis | Oct 2027 |
| University of Michigan Rogel Cancer Center | Natalizumab Integrin alpha-4/beta-7 inhibitor; Integrin alpha-4/beta-1 inhibitor | ITGA4, ITGB7, ITGB1 | Phase 2 | Recurrent Diffuse Large B-Cell Lymphoma | May 2028 |
| Oorja Bio | ORJ-001 β1 integrin agonist peptide | ITGB1 | Phase 2 | Idiopathic Pulmonary Fibrosis | Jan 2029 |
Idiopathic Pulmonary Fibrosis (1) Recurrent Diffuse Large B-Cell Lymphoma (1) Multiple Sclerosis (1) Multiple Sclerosis, Relapsing-Remitting (1)
mixed (2), small molecule (1), antibody (1)
Oorja Bio (1) University of Michigan Rogel Cancer Center (1) Queen Mary University of London (1) The Cleveland Clinic (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.